News Lilly loses bid to nix $184m Medicaid fraud penalty Lilly has lost an appeal in a whistleblower lawsuit that alleged it had defrauded Medicaid by underpaying rebates.
News Intercept pulls Ocaliva off the market in the US Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.
News AbbVie lifted by lengthy delay to generics of Rinvoq Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.
News J&J claims FDA okay for bladder cancer drug TAR-200 Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News Zentiva set to change hands in €4.1bn private equity deal Ex-Sanofi generics company Zentiva is poised for a sale by current owner Advent International to US investment group GTCR, says a media report.
News Pharma says UK is 'tumbling down' rankings for investment The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.
News Obesity-focused biotech Kailera joins IPO queue in US Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
